The scope of liquid biopsy in the clinical management of oral cancer

With increasing knowledge on molecular tumour information, precision oncology has revolutionised the medical field over the past years. Liquid biopsy entails the analysis of circulating tumour components, such as circulating tumour DNA, tumour cells or tumour-derived extracellular vesicles, and has thus come as a handy tool for personalised medicine in many cancer entities. Clinical applications under investigation include early cancer detection, prediction of treatment response and molecular monitoring of the disease, for example, to comprehend resistance patterns and clonal tumour evolution. In fact, several tests for blood-based mutation profiling are already commercially available and have entered the clinical field.In the context of hepatocellular carcinoma, where access to tissue specimens remains mostly limited to patients with early stage tumours, liquid biopsy approaches might be particularly helpful. A variety of translational liquid biopsy studies have been carried out to address clinical needs, such as early hepatocellular carcinoma detection and prediction of treatment response. To this regard, methylation profiling of circulating tumour DNA has evolved as a promising surveillance tool for early hepatocellular carcinoma detection in populations at risk, which might soon transform the way surveillance programmes are implemented. This review summarises recent developments in the liquid biopsy oncological space and, in more detail, the potential implications in the clinical management of hepatocellular carcinoma. It further outlines technical peculiarities across liquid biopsy technologies, which might be helpful for interpretation by non-experts.

Download Full-text

Liquid biopsy in the clinical management of bladder cancer: current status and future developments

Expert Review of Molecular Diagnostics ◽

10.1080/14737159.2019.1680284 ◽

2019 ◽

Vol 20 (2) ◽

pp. 255-264 ◽

Cited By ~ 1

Author(s):

Erik Kouba ◽

Antonio Lopez-Beltran ◽

Rodolfo Montironi ◽

Francesco Massari ◽

Kun Huang ◽

...

Keyword(s):

Bladder Cancer ◽

Liquid Biopsy ◽

Clinical Management ◽

Current Status ◽

Future Developments

Download Full-text

Abstract 3139: Liquid biopsy (ctDNA) testing in clinical management of solid cancers: 5-years of experience

10.1158/1538-7445.am2016-3139 ◽

2016 ◽

Author(s):

Lucie Benesova ◽

Barbora Belsanova ◽

Tereza Halkova ◽

Jiri Pudil ◽

Bohus Bunganic ◽

...

Keyword(s):

Liquid Biopsy ◽

Clinical Management ◽

Years Of Experience

Download Full-text

Integrating comprehensive genomic profiling into the clinical management of prostate cancer patients: A single institution community practice experience.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.6_suppl.281 ◽

2020 ◽

Vol 38 (6_suppl) ◽

pp. 281-281

Author(s):

Neal D. Shore ◽

James Haberberger ◽

Eric Allan Severson ◽

Brian Michael Alexander ◽

Pratheesh Sathyan ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Liquid Biopsy ◽

Clinical Management ◽

Additional Patient ◽

Genomic Profiling ◽

Data Set ◽

Tissue Samples ◽

Comprehensive Genomic Profiling ◽

Germline Testing

281 Background: Prostate cancer is a leading cause of cancer-related mortality with a 5-year survival rate of 69%. In this study, we examine the role of integrating CGP, including tissue and liquid biopsy testing, into the clinical management of prostate cancer patients. Methods: We analyzed 140 cases of advanced prostate carcinoma with tissue and ctDNA based Comprehensive Genomic Profiling (CGP). CGP analysis revealed genomic alterations (GAs), TMB and MSI status. Germline testing, using multiple commercially assays was also obtained. Results: The median age of patients tested by tissue-based and liquid-based CGP was 65 years (46 to 85 yrs) and 69 years (51 to > 89 years), respectively. CGP analysis of tissue samples revealed the most commonly altered genes to be TP53 (34.6%), TMPRSS2- ERG (25.9%), PTEN (23.5%), NBN (14.8%), MYC (13.6%), BRCA2 (14.3%) and CDKN2A (13.3%). TMB analysis determined in 77 tissue samples showed a median (mean) value of 2.61 (5.00) mutations/Mb. 3.9% cases (3/77) were found to be hypermutated. MSI status was determined in 74 cases of which 2.7% (2/74) were found to be MSI-High. Of the tissue-based samples tested, 30.9% (25/81) were derived from metastatic sites. Analysis of commonly altered genes between primary vs metastatic tissue samples revealed TP53 mutations were significantly enriched in metastatic tumors. CGP analysis of the 59 liquid biopsy samples revealed the most commonly altered genes to be TP53 (37.3%), NF1 (10.2%), ATM (10.2%), CHEK2 (8.5%) and GNAS (8.5%). Germline testing was performed as described above on a clinically indicated subset of patients, which revealed alterations in BRCA, ATM, CHEK2, BRIP1 and TP53, among others. We are evaluating additional patient samples as part of the data set, which will be added to the final abstract presentation with a cutoff date of 12-31-2019. Conclusions: Genomic testing for high risk and advanced prostate cancer patients per the NCCN recommendations, with somatic testing, using tissue and liquid biopsy testing, as well as germline testing in selected cases, identifies DNA alterations which have potential clinical utility for clinical trial enrollment.

Download Full-text

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Frontiers in Genetics ◽

10.3389/fgene.2021.634642 ◽

2021 ◽

Vol 12 ◽

Author(s):

Wei Gao ◽

Yigui Chen ◽

Jianwei Yang ◽

Changhua Zhuo ◽

Sha Huang ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Tumor Cells ◽

Clinical Outcomes ◽

Peripheral Blood ◽

Liquid Biopsy ◽

Clinical Management ◽

Therapy Response ◽

Clinical Benefits

Liquid biopsy, which generally refers to the analysis of biological components such as circulating nuclear acids and circulating tumor cells in body fluids, particularly in peripheral blood, has shown good capacity to overcome several limitations faced by conventional tissue biopsies. Emerging evidence in recent decades has confirmed the promising role of liquid biopsy in the clinical management of various cancers, including colorectal cancer, which is one of the most prevalent cancers and the second leading cause of cancer-related deaths worldwide. Despite the challenges and poor clinical outcomes, patients with metastatic colorectal cancer can expect potential clinical benefits with liquid biopsy. Therefore, in this review, we focus on the clinical prospects of liquid biopsy in metastatic colorectal cancer, specifically with regard to the recently discovered various biomarkers identified on liquid biopsy. These biomarkers have been shown to be potentially useful in multiple aspects of metastatic colorectal cancer, such as auxiliary diagnosis of metastasis, prognosis prediction, and monitoring of therapy response.

Download Full-text

Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer

Biology ◽

10.3390/biology9110379 ◽

2020 ◽

Vol 9 (11) ◽

pp. 379

Author(s):

Salvatore Crimi ◽

Luca Falzone ◽

Giuseppe Gattuso ◽

Caterina Maria Grillo ◽

Saverio Candido ◽

...

Keyword(s):

Oral Cancer ◽

Cancer Patients ◽

Liquid Biopsy ◽

Digital Pcr ◽

Droplet Digital Pcr ◽

Pcr Analysis ◽

Screening Programs ◽

Diagnostic Potential ◽

Oral Cancer Patients

Despite the availability of screening programs, oral cancer deaths are increasing due to the lack of diagnostic biomarkers leading to late diagnosis and a poor prognosis. Therefore, there is an urgent need to discover novel effective biomarkers for this tumor. On these bases, the aim of this study was to validate the diagnostic potential of microRNAs (miRNAs) through the analysis of liquid biopsy samples obtained from ten oral cancer patients and ten healthy controls. The expression of four selected miRNAs was evaluated by using droplet digital PCR (ddPCR) in a pilot cohort of ten oral cancer patients and ten healthy donors. Bioinformatics analyses were performed to assess the functional role of these miRNAs. The expression levels of the predicted down-regulated hsa-miR-133a-3p and hsa-miR-375-3p were significantly reduced in oral cancer patients compared to normal individuals while no significant results were obtained for the up-regulated hsa-miR-503-5p and hsa-miR-196a-5p. ROC analysis confirmed the high sensitivity and specificity of hsa-miR-375-3p and hsa-miR-133a-3p. Therefore, both miRNAs are significantly down-regulated in cancer patients and can be used as biomarkers for the early diagnosis of oral cancer. The analysis of circulating miRNAs in a larger series of patients is mandatory to confirm the results obtained in this pilot study.

Download Full-text